| 标题 |
专利、报告等 Abstract LB318: SB-4826, a first-in-class oral, covalent inhibitor of SUMO E1 that induces IFN signaling and inhibits tumor growth as monotherapy and in combination with immune checkpoint blockade |
| 备注 |
需要会议poster
💡 该求助存在备注,如果存在信息冲突,请以备注为准
|
| 网址 | |
| DOI | |
| 其它 |
期刊:Cancer Research 作者:Jude R. Canon; Ashley Callinan; Sarah Bradley; Laurie Wang; Mackenzie Kui; et al 出版日期:2023 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)